| Literature DB >> 27433490 |
Aline Fernanda Barbosa Bernardo1, Luiz Carlos M Vanderlei1, David M Garner2.
Abstract
This study's aim is to analyze heart rate dynamics in subjects with chronic obstructive pulmonary disease (COPD) by measures of heart rate variability (HRV). HRV is a simple and noninvasive measure of autonomic impulses. 38 adults were divided into two equal groups based on respiratory function: COPD and normal. HRV was monitored in the supine position for 30 minutes. After tests of normality, Kruskal-Wallis was used for the statistical analysis, with the level of significance set at P < 0.05. Principal component analysis identified two components representing 99.5% of total variance. Furthermore, it is suggested that the chaos forward parameter (CFP) which applies all three "chaotic globals" is the most influential, although others are statistically more significant. The COPD subjects exhibited a decrease in the CFP. COPD can be termed a dynamical condition, decreasing the chaotic response. The perceived benefits of such analysis include quantitative assessment and suitable pharmacological intervention in the respiratory condition, especially of other related dynamical diseases such as cardiac failure.Entities:
Year: 2014 PMID: 27433490 PMCID: PMC4897192 DOI: 10.1155/2014/673232
Source DB: PubMed Journal: Int Sch Res Notices ISSN: 2356-7872
Figure 1A Welch method power spectrum of a 1000 ECG RR intervals of a COPD patient.
Figure 2A multitaper method power spectrum of 1000 ECG RR intervals of a COPD patient.
Figure 3The boxplot illustrates the mean values and standard deviation of CFP for normal subjects RR intervals. The mean value is indicated by the (+) symbol in the boxplot.
Figure 4The boxplot illustrates the mean values and standard deviation of CFP for the RR intervals of COPD subjects. Mean values are indicated by the (+) symbol.
The table below shows the first (Q1) and third (Q3) quartiles of [CFPx 1–7] for the normal and COPD subjects in 1000 RR intervals. The statistical significance Kruskal-Wallis test is applied. A nonparametric test.
| [CFP | Normal Q1 | Normal Q3 | COPD Q1 | COPD Q3 | Kruskal-Wallis |
|---|---|---|---|---|---|
| 1 | 0.8130 | 0.9680 | 0.7060 | 0.9841 | 0.1116 |
| 2 | 0.5362 | 0.5953 | 0.5421 | 0.6530 | 0.3502 |
| 3 | 0.7427 | 0.8877 | 0.5648 | 0.7458 | 0.0005 |
| 4 | 0.6300 | 0.8769 | 0.5977 | 0.9079 | 0.9651 |
| 5 | 0.2919 | 0.4683 | 0.4034 | 0.6088 | 0.0072 |
| 6 | 0.5583 | 0.7414 | 0.4412 | 0.6735 | 0.0749 |
| 7 | 0.2721 | 0.4898 | 0.1448 | 0.3451 | 0.0066 |
The table below is the principal component analysis for CFP for seven groups for 19 subjects who are suffering from COPD. PC1 represents the first principal component, PC2 the second, until the seventh component PC7.
| Variable | PC1 | PC2 | PC3 | PC4 | PC5 | PC6 | PC7 |
|---|---|---|---|---|---|---|---|
| CFP1 | 0.357 | −0.409 | 0.105 | −0.639 | 0.202 | −0.141 | −0.474 |
| CFP2 | 0.045 | −0.590 | 0.660 | 0.248 | 0.017 | 0.272 | 0.281 |
| CFP3 | 0.197 | −0.544 | −0.501 | 0.496 | 0.002 | −0.408 | −0.041 |
| CFP4 | 0.486 | 0.075 | −0.028 | −0.320 | −0.211 | −0.294 | 0.724 |
| CFP5 | 0.448 | 0.239 | 0.312 | 0.282 | −0.619 | −0.105 | −0.413 |
| CFP6 | 0.489 | −0.007 | −0.385 | 0.050 | 0.042 | 0.780 | 0.009 |
| CFP7 | −0.394 | −0.355 | −0.237 | −0.315 | −0.727 | 0.186 | 0.017 |